(CN106459975) 1. One AON a peptide-conjugated compound, a compound comprising at least two AON, AON compound of formula (I), (II), (III), (IV), (V) or (VI) 15 to 30 subunits in length to, Wherein B is selected from C, G, A or T naturally occurring purine or pyrimidine nucleotide base; Wherein at least two AON compounds have the target front-mRNA or mRNA nucleotide complementary to the nucleotide base sequence of at least 75%; Wherein at least two AON 0 to 3 repeating subunits of a compound having, wherein B is a G; Wherein at least two AON compound has less than 60% of the subunits, wherein B is a C or G; Wherein at least two compounds having a non-self-complementary sequence AON; with Wherein at least two AON compound with conjugated poly-cationic peptide. 2. One a peptide-conjugated phosphorus diamide compound mo, comprising at least two phosphorous diamide a morpholino compound, the phosphorus compound the diamide mo formula (I) 15 to 30 subunits of the: Wherein R is a alkyl and B is selected from C, G, A or T naturally occurring purine or pyrimidine nucleotide base; Wherein at least two phosphorous diamide mo target compound has the front-mRNA or mRNA of at least 8 contiguous bases complementary to the nucleotide base sequence; Wherein at least two phosphorus diamide compound having repeating subunits of 0 to 3 mo, wherein B is a G; Wherein at least two phosphorus compound has less than 60% of the subunits of the diamide mo, wherein B is a C or G; Wherein at least two phosphorus diamide compound having a non-self-complementary sequence mo; with Wherein at least two phosphorus diamide compound with the poly-cationic peptide conjugated mo.
最新评论
暂无评论。